The leader in computerized cognitive testing.
CDR System®
A new generation of computerized cognitive testing
The Signant SmartSignals® CDR System® revolutionized how we measure changes in cognition in clinical trials. Over 35 years ago, the CDR System was the first computerized solution to challenge paper-and-pencil neuropsychological testing, providing groundbreaking millisecond reaction time and secure data capture. Since then, its widespread adoption has generated the industry’s largest normative database, spanning the broadest range of therapeutic areas, and facilitating meaningful interpretation of test findings.
Our next generation web-based solution uses keyboard input to deliver the same proven speed and accuracy of its predecessor solution, with easier logistics and administration. This was driven by significant research into evolving industry needs and investment into the next generation release of the most widely validated in clinical trials.
Identify subtle cognitive changes
Measure major cognitive domains
Precisely assess working and episodic memory, attention, and executive function tasks relevant in everyday life.
Detect subtle changes early
Administer this highly sensitive battery of computerized cognition tasks, specifically designed for clinical trials, repeatedly throughout your study to identify changes in cognitive function in any participant population.
Complete assessments quickly
Each assessment is brief to complete (30 minutes or less depending on the content of the battery) thus reducing participants testing burden.
Assess your drug's cognitive safety
Signant’s attention tests have been used in over 500 cognitive safety assessments over the last 35 years, some of which were used to support product labeling, across a broad range of therapy areas. The cognitive safety battery includes the following tests:
Simple reaction time
Measures alertness and the ability to focus concentration
Digital vigilance
Measures sustained and intensive attention
Choice reaction time
Measures alertness, the ability to focus concentration, and information processing
Why choose Signant’s CDR System to support your Phase I study?
Reliable Data
The Signant SmartSignals CDR System produces data that is more reliable and measurable than paper-based methods.
Industry-Leading Database
Signant’s industry-leading normative database and extensive list of publications (and papers) will enhance interpretation of your data.
Scientific Expertise
Signant’s CDR System is provided with our scientific expertise to help you understand and assess the effect of your drug/therapy on cognitive function and safety.
Fast Administration
Signant’s CDR System attention battery can be administered in less than ten minutes by non-specialists. The battery content can be tailored to your protocol’s needs, and data are automatically uploaded to a secure database and immediately available for analysis.
FAQs
How are cognitive changes assessed in clinical trial patients?
Cognitive function and changes are assessed using three general approaches: self-report, informant-report, and performance-based measures. Many scales and questionnaires, such as ECog, are commonly used to measure general cognitive function as well as indication-specific cognition, such as ADAS-COG in dementia studies. Other approaches include sensitive computerized clinical assessment batteries designed to detect subtle cognitive changes that can be applied in any trial for any indication.
What is included in a clinical trial cognitive assessment?
While scales and questionnaires vary depending on their purpose, cognitive assessments generally test working memory, episodic memory, attention, tasks, and functions required for everyday life, such as problem-solving and personal care.
What is the purpose of a cognitive test in clinical trials?
Cognitive assessments are used to detect subtle changes in cognitive function, such as impairment or improvements, to determine a treatment’s effect in patients.
What population can this system assess?
Our web-enabled CDR System is a disease-agnostic tool that can provide cognitive testing for any type of population, from healthy volunteers and patients with minor cognitive impairment to patients with dementia.
Can you assess cognitive deficit, cognitive improvement, or both using the SmartSignals CDR System
Featuring bidirectional sensitivity, the CDR System can assess potential deficit and improvement in cognition as exemplified by frequent use in Phase I clinical research studies.
Explore the Signant SmartSignals® CDR System®
Safeguard your drug's cognitive safety with precision using our cutting-edge web-based solution, featuring validated cognitive tests for accurate, sensitive, and interpretable insights vital for drug development.